Brief: 9 Meters Biopharma Reports Q3 Loss Per Share $0.06

9 Meters Biopharma

09/11/2020 14:47

Nov 9 (Reuters) - 9 Meters Biopharma Inc  NMTR.O :
    * Q3 LOSS PER SHARE $0.06
    * PHASE 1B/2A TRIAL WITH A PROPRIETARY LONG-ACTING GLP-1
AGONIST
IN SHORT BOWEL SYNDROME TOP-LINE DATA EXPECTED IN Q4
    * CONTINUED ENROLLMENT OF PHASE 3 TRIAL WITH LARAZOTIDE IN
CELIAC
DISEASE, INTERIM ANALYSIS REMAINS ON TARGET FOR 1H 2021
    * AS OF SEPT 30, 2020, CO'S CASH AND CASH EQUIVALENTS
TOTALED
ABOUT $12.4 MILLION
    * Q3 EARNINGS PER SHARE VIEW $-0.06 -- REFINITIV IBES DATA

Source text for Eikon: [ID:https://bit.ly/3ldCqOT]
Further company coverage:  NMTR.O 

 ((Reuters.Briefs@thomsonreuters.com;))